Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5913MR)

This product GTTS-WQ5913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5913MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10211MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ71MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ11663MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ15621MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ6635MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ47MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ7493MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ2424MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW